Alx Oncology Holdings Inc Dossier
Qualitative Analysis
Business overview
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune systems. The company's lead product candidate is evorpacept, a next-generation CD47-blocking biologic designed to combine a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain to minimize hematologic toxicities. ALX Oncology is evaluating evorpacept in combination with anti-cancer antibodies, antibody-drug conjugates (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors across multiple clinical trials. Its second pipeline candidate is ALX2004, a novel EGFR-targeted ADC currently in Phase 1 clinical development.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing clinical development of evorpacept in patient populations with high CD47 expression, following exploratory analyses showing that clinical responses are largely restricted to these patients.
Expected impact: Increases the probability of clinical success and optimizes trial designs for future Phase 3 registrational studies.
Streamlining clinical programs to focus resources on the ASPEN-09-Breast study and core evorpacept combinations while reducing other non-core trial activities, building on the ~30% workforce reduction executed in early 2025.
Expected impact: Significantly reduced R&D and personnel expenses, narrowing quarterly net losses and extending the cash runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Evaluating evorpacept in combination with Jazz's investigational bispecific antibody, zanidatamab, for HER2-positive breast cancer.
Terms: Supply agreement and shared clinical development insights.
Collaborating to supply foundational anti-cancer antibodies for combination trials with evorpacept, reducing development costs and validating combination regimens.
Terms: Drug supply collaboration.